Plenary Session—The Patient Journey: Equity of Cancer Care
Search for other papers by Thomas A. Farrington in
Current site
Google Scholar
PubMed
Search for other papers by Liz Margolies in
Current site
Google Scholar
PubMed
Search for other papers by Shonta Chambers in
Current site
Google Scholar
PubMed
Search for other papers by Maria D. Garcia-Jimenez in
Current site
Google Scholar
PubMed
Search for other papers by Alyssa A. Schatz in
Current site
Google Scholar
PubMed
Search for other papers by Carmen E. Guerra in
Current site
Google Scholar
PubMed
Many people with cancer have benefited from the host of therapeutic and research advances across many different tumor types over the past decades. However, not every patient with cancer is afforded the opportunity for such treatments, and there is an assortment of notable barriers to the delivery of equitable care for all. To address the complexity of this important issue in contemporary cancer care, a distinguished panel at the NCCN 2022 Annual Conference, moderated by Carmen E. Guerra, MD, MSCE, explored this topic from several different vantage points, including the patient perspective and the view from inside the LGBTQ+ community. In addition, several panel members explored the constructive steps and initiatives being taken in the clinical, research, and policy realms to improve access to care for all patients with cancer, as well as overall health equity.
Disclosures: Mr. Farrington has disclosed receiving honoraria from Bayer HealthCare, Genomic Health, Inc., Janssen Pharmaceutica Products, LP, and Pfizer Inc. Ms. Margolies has disclosed receiving grant/research support from Bristol-Myers Squibb Company, Genentech, Inc., and Syros Pharmaceuticals. Dr. Garcia-Jimenez has disclosed receiving grant/research support from Merck & Co., Inc. Ms. Chambers and Ms. Schatz have disclosed having no relevant financial relationships. Dr. Guerra has disclosed receiving grant/research support from Bristol Myers Squibb Foundation; and serving as a scientific advisor for Freenome, Inc., GlaxoSmithKline, Grail, and Guardant Health.
© 2019-2024 National Comprehensive Cancer Network